Akito Oshima
A5000956848- Glioma Diagnosis and Treatment
- Heat shock proteins research
- Signaling Pathways in Disease
- FOXO transcription factor regulation
- Brain Metastases and Treatment
- Melanoma and MAPK Pathways
- Meningioma and schwannoma management
- Liver Diseases and Immunity
- Virus-based gene therapy research
- Radiopharmaceutical Chemistry and Applications
- Pediatric Hepatobiliary Diseases and Treatments
- Single-cell and spatial transcriptomics
- Abdominal vascular conditions and treatments
- Intracerebral and Subarachnoid Hemorrhage Research
- Neurosurgical Procedures and Complications
- Adrenal and Paraganglionic Tumors
- Intracranial Aneurysms: Treatment and Complications
- Pancreatitis Pathology and Treatment
- Cancer, Hypoxia, and Metabolism
- CNS Lymphoma Diagnosis and Treatment
- IgG4-Related and Inflammatory Diseases
- Gallbladder and Bile Duct Disorders
- interferon and immune responses
- Ocular Oncology and Treatments
- Neurofibromatosis and Schwannoma Cases
Yokohama City University
1996-2024
Hodogaya Chemical (Japan)
2024
NTT Medical Center
2017-2022
Yokohama City University Medical Center
2021
Kanagawa Cancer Center
2021
Yokohama City University Hospital
2010-2021
Kanagawa Prefectural Hospital Organization
2021
To detect and identify adenovirus (Ad), we used a combination of PCR restriction fragment length polymorphism (RFLP) analysis. Nested with two primer sets that hybridize to the conserved region for hexon proteins 14 prototypes Ad, Ad serotype 1 (Ad1) Ad8, -11, -14, -19, -37, -40, -41, amplified 956-bp DNA fragment. The fragments from were completely differentiated three endonucleases, EcoT14I, HaeIII, HintI. We applied this new method 127 samples conjunctival scrapings patients...
Abstract Purpose: Molecular targeted therapy using BRAF and/or MEK inhibitors has been applied to BRAFV600E-mutant high-grade gliomas (HGG); however, the therapeutic effect is limited by emergence of drug resistance. Experimental Design: We established multiple paired HGG patient-derived xenograft models based on tissues collected prior and at relapse after molecular therapy. Using these models, we dissected treatment-resistant mechanisms for explored targets overcome resistance in BRAFV600E...
Abstract Background This study aimed to investigate what treatment are selected for malignant brain tumors, particularly glioblastoma (GBM) and primary central nervous system lymphoma (PCNSL), in real-world Japan the costs involved. Methods We conducted a questionnaire survey regarding selections newly diagnosed GBM PCNSL treated between July 2021 June 2022 among 47 institutions Clinical Oncology Group-Brain Tumor Study Group. calculated total cost per month of initial therapy or PCNSL....
Abstract Purpose: The 2021 World Health Organization (WHO) classification of central nervous system (CNS) tumors uses an integrated approach involving histopathology and molecular profiling. Because majority adult malignant brain are gliomas primary CNS lymphomas (PCNSL), rapid differentiation these diseases is required for therapeutic decisions. In addition, diffuse require information on single-nucleotide variants (SNV), such as IDH1/2. Here, we report intraoperative diagnostic (i-ID) to...
<p>Single nucleotide detection threshold</p>
<p>Illustrative cases in the retrospective cohort</p>
<div>AbstractPurpose:<p>The 2021 World Health Organization (WHO) classification of central nervous system (CNS) tumors uses an integrated approach involving histopathology and molecular profiling. Because majority adult malignant brain are gliomas primary CNS lymphomas (PCNSL), rapid differentiation these diseases is required for therapeutic decisions. In addition, diffuse require information on single-nucleotide variants (SNV), such as <i>IDH1</i>/2. Here, we report...
<p>Single nucleotide detection threshold</p>
<div>AbstractPurpose:<p>The 2021 World Health Organization (WHO) classification of central nervous system (CNS) tumors uses an integrated approach involving histopathology and molecular profiling. Because majority adult malignant brain are gliomas primary CNS lymphomas (PCNSL), rapid differentiation these diseases is required for therapeutic decisions. In addition, diffuse require information on single-nucleotide variants (SNV), such as <i>IDH1</i>/2. Here, we report...
<p>Summary of the retrospective cohort</p>
<p>qPCR-based CDKN2A genotyping</p>
<p>qPCR-based CDKN2A genotyping</p>
<p>Genomic profiling of EGFR, PTEN, and TERT in IDH-wildtype lower-grade astrocytomas</p>
<p>Illustrative cases in the retrospective cohort</p>
<p>Genomic characterization of chromosome 1p/19q and TERT promoter status in IDH mutant glioma cases</p>